Top of this page
Skip navigation, go straight to the content

Our Science Olokizumab

Clinical Study Information - olokizumab

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Crohn's Disease A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease Phase 2 CD0001
Terminated
NCT01635621
2011-002517-11
Rheumatoid Arthritis Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 RA0056
Completed
NCT01242488
2010-020839-39
Genovese, M. C. et al. Ann Rheum Dis;2014;73;9;1607-1615
Rheumatoid Arthritis Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056 Phase 2 RA0057
Completed
NCT01296711
2010-022224-77
Rheumatoid Arthritis Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 RA0083
Completed
NCT01463059 Takeuchi, T.et al. Mod Rheumatol;9-10-2015;1-9
Rheumatoid Arthritis The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis Phase 2 RA0089
Completed
NCT01533714